Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 107

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 107
---
 hydrogel platform for the local repair of damaged cartilage and bone.

We have experienced
net losses in every period since our inception in 2004, except for 2024 due to changes in fair value of convertible notes, warrant
liability and an approval received from the European Commission Executive Agency for Small and Medium-sized Enterprises, or EASME in
2024 which resulted in a recognition of approximately $2 million research and development expense reduction. We incurred net income of $5.2 million and a net
losses $4.1 million for the year ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and December 31, 2023, we
had an accumulated deficit of $41.7 million and $46.9 million, respectively. We anticipate that we will continue to incur
significant losses for the foreseeable future as our operating expenses and capital expenditures increase substantially due to our
continued investment in our research and development activities and as we hire additional employees over the coming years.
Furthermore, upon closing of this offering, we expect to incur additional expenses associated with operating as a public company on
the NYSE American, including significant legal, accounting, investor relations and other expenses.

For further information regarding
our business and operations, see “Business” below.

Components of Operating Results

Revenues

We have not recognized any
revenue to date, and we do not expect to generate revenue from the sale of products in the near future.

Research and Development Expenses

Research and development
activities are our primary focus. We do not believe that it is possible at this time to accurately project total expenses required for
us to reach the point at which we will be ready to out-license our technologies. Development timelines, the probability of success and
development costs can differ materially from expectations. In addition, we cannot forecast whether and when collaboration arrangements
will be entered into, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We
also received non-royalty bearing grant from the European Union through the European Commission Executive Agency for Small and Medium-sized
Enterprises as part of the Horizon 2020 Research and Innovative Framework Programme, or the Horizon 2020 Grant. The Horizon 2020 Grant
was fully recognized in the year ended December 31, 2024, as a reduction in research and development expense. We expect our research
and development expenses to increase over the next several years as our development